Page 818 - Read Online

Page 12 of 15 Alqahtani et al. Hepatoma Res 2020;6:70 I http://dx.doi.org/10.20517/2394-5079.2020.65

Copyright
© The Author(s) 2020.

REFERENCES
1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014;383:2168-79.
2. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, et al. Cholangiocarcinoma: thirty-one-year experience with 564
patients at a single institution. Ann Surg 2007;245:755-62.
3. Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol 2016;27:v28-37.
4. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new
concept. World J Hepatol 2010;2:419-27.
5. Petrick JL, Yang B, Altekruse SF, Van Dyke AL, Koshiol J, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the
United States: a population-based study in SEER-Medicare. PLoS One 2017;12:e0186643.
6. Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control
2017;24:1073274817729245.
7. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for
intrahepatic cholangiocarcinoma. J Hepatol 2012;57:69-76.
8. Lee BS, Cha BH, Park EC, Roh J. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study. Liver Int
2015;35:1048-53.
9. Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, et al. New and emerging systemic therapeutic options for advanced
cholangiocarcinoma. Cells 2020;9:688.
10. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-84.
11. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and
determinants of outcome after resection. Ann Surg 2008;248:84-96.
12. Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected
biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 2019;37:658-67.
13. Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus
observation in resected bile duct cancer. Br J Surg 2018;105:192-202.
14. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, et al. Capecitabine compared with observation in resected biliary tract cancer
(BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-73.
15. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to
observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a
randomized, multidisciplinary, multinational phase III trial. BMC Cancer 2015;15:564.
16. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.
J Clin Oncol 2012;30:1934-40.
17. Kiefer MV, Albert M, McNally M, Robertson M, Sun W, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum,
doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011;117:1498-505.
18. Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, et al. Treatment of unresectable cholangiocarcinoma: conventional
transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J
Gastroenterol Hepatol 2012;24:437-43.
19. Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment
of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 2011;66:322-8.
20. Hoffmann RT, Paprottka PM, Schön A, Bamberg F, Haug A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with
unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012;35:105-16.
21. Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory
intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013;36:440-8.
22. Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic
review and meta-analysis. HPB (Oxford) 2017;19:741-8.
23. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical
practice guideline. J Clin Oncol 2019;37:1015-27.
24. Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, et al. Chemotherapy improves survival and quality of life in advanced
pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
25. Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II
study. Jpn J Clin Oncol 2005;35:68-73.
26. Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, et al. Treatment efficacy/safety and prognostic factors in patients with advanced
biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology 2010;79:39-45.
27. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in
inoperable biliary tract carcinoma. Ann Oncol 2005;16:279-81.
28. Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E, et al. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree